-
1.发明授权Compound for the antemortem diagnosis of Alzheimer's Disease and in vivo imaging and prevention of amyloid deposition 失效用于阿尔茨海默氏病的止血诊断和体内成像和预防淀粉样蛋白沉积的化合物
公开(公告)号：US6114175A
公开(公告)日：2000-09-05
申请号：US188244
申请日：1998-11-09
IPC分类号： A61K31/32 , A61K31/60 , A61K31/655 , A61K49/06 , A61M36/14 , C07B59/00 , C07C63/66 , C07C65/03 , C07C65/19 , C07C65/28 , C07C69/88 , C07C69/94 , C07D209/48 , C07D217/24 , C07D221/10 , C07D221/14 , C07D237/28 , C07D237/32 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/14 , C07D265/26 , C07D271/10 , C07F7/22 , C07F7/24 , C09B23/14 , G01N33/48 , G01N33/68
CPC分类号： C07D209/48 , A61K49/06 , C07B59/001 , C07B59/002 , C07C63/66 , C07C69/94 , C07D217/24 , C07D221/14 , C07D237/28 , C07D237/32 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/14 , C07D265/26 , C07D271/10 , C07F7/2212 , C09B23/141 , G01N33/6896 , G01N2800/2821
摘要： Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
摘要翻译： 描述了作为Chrysamine G的非偶氮衍生物的淀粉样蛋白结合化合物，含有药物组合物的方法，以及使用这些化合物在体内鉴定阿尔茨海默氏症并诊断特征为淀粉样变性的其它病理状态如唐氏综合征的方法。 还描述了含有Chrysamine G的非偶氮衍生物的药物组合物和使用这种组合物在淀粉样变性相关病症中预防细胞变性和淀粉样蛋白诱导的毒性的方法。 还描述了使用非偶氮Chrysamine G衍生物在活组织检查或尸检组织中染色或检测淀粉样蛋白沉积物的方法。 还描述了使用非偶氮Chrysamine G衍生物来量化活组织检查和死后组织匀浆中的淀粉样沉积物的方法。
-
2.发明授权Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition 失效烷基，烯基和炔基Chrysamine G衍生物用于阿尔茨海默氏病的止血诊断和体内成像和预防淀粉样蛋白沉积公开(公告)号：US06168776A
公开(公告)日：2001-01-02
申请号：US08837494
申请日：1997-04-18
IPC分类号： A61K4902
CPC分类号： C07D209/48 , A61K49/06 , C07B59/001 , C07B59/002 , C07C63/66 , C07C69/94 , C07D217/24 , C07D221/14 , C07D237/28 , C07D237/32 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/14 , C07D265/26 , C07D271/10 , C07F7/2208 , C09B23/141 , G01N33/6896 , G01N2800/2821
摘要： Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
摘要翻译： 描述了作为Chrysamine G的非偶氮衍生物的淀粉样蛋白结合化合物，含有药物组合物的方法，以及使用这些化合物在体内鉴定阿尔茨海默氏症并诊断特征为淀粉样变性的其它病理状态如唐氏综合征的方法。 还描述了含有Chrysamine G的非偶氮衍生物的药物组合物和使用这种组合物在淀粉样变性相关病症中预防细胞变性和淀粉样蛋白诱导的毒性的方法。 还描述了使用非偶氮Chrysamine G衍生物在活组织检查或尸检组织中染色或检测淀粉样蛋白沉积物的方法。 还描述了使用非偶氮Chrysamine G衍生物来量化活组织检查和死后组织匀浆中的淀粉样沉积物的方法。
-
3.发明授权Alkyl, alkenyl and alkynyl chrysamine G derivatives for inhibition of cell degeneration and toxicity associated with amyloid deposition 失效用于抑制与淀粉样蛋白沉积相关的细胞变性和毒性的烷基，烯基和炔基奎胺C衍生物
公开(公告)号：US6133259A
公开(公告)日：2000-10-17
申请号：US188200
申请日：1998-11-09
IPC分类号： A61K31/32 , A61K31/60 , A61K31/655 , A61K49/06 , A61M36/14 , C07B59/00 , C07C63/66 , C07C65/03 , C07C65/19 , C07C65/28 , C07C69/88 , C07C69/94 , C07D209/48 , C07D217/24 , C07D221/10 , C07D221/14 , C07D237/28 , C07D237/32 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/14 , C07D265/26 , C07D271/10 , C07F7/22 , C07F7/24 , C09B23/14 , G01N33/48 , G01N33/68 , A61N25/28
CPC分类号： C07D209/48 , A61K49/06 , C07B59/001 , C07B59/002 , C07C63/66 , C07C69/94 , C07D217/24 , C07D221/14 , C07D237/28 , C07D237/32 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/14 , C07D265/26 , C07D271/10 , C07F7/2212 , C09B23/141 , G01N33/6896 , G01N2800/2821
摘要： Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
摘要翻译： 描述了作为Chrysamine G的非偶氮衍生物的淀粉样蛋白结合化合物，含有药物组合物的方法，以及使用这些化合物在体内鉴定阿尔茨海默氏症并诊断特征为淀粉样变性的其它病理状态如唐氏综合征的方法。 还描述了含有Chrysamine G的非偶氮衍生物的药物组合物和使用这种组合物在淀粉样变性相关病症中预防细胞变性和淀粉样蛋白诱导的毒性的方法。 还描述了使用非偶氮Chrysamine G衍生物在活组织检查或尸检组织中染色或检测淀粉样蛋白沉积物的方法。 还描述了使用非偶氮Chrysamine G衍生物来量化活组织检查和死后组织匀浆中的淀粉样沉积物的方法。
-
4.发明授权Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 失效淀粉样蛋白结合氮连接化合物用于阿尔茨海默病的止血诊断，体内成像和预防淀粉样蛋白沉积公开(公告)号：US06417178B1
公开(公告)日：2002-07-09
申请号：US08968902
申请日：1997-11-06
IPC分类号： C07C24510
CPC分类号： C07D209/48 , A61K49/10 , A61K51/0402 , C07C229/64 , C07C233/87 , C07C243/22 , C07C245/08 , C07C245/10 , C07C251/24 , C07C251/86 , C07C2603/18 , C07C2603/24 , C07D217/24 , C07D221/14 , C07D237/26 , C07D257/04 , C07D261/20 , C07D265/02 , C07D265/26 , C07D271/10 , G01N33/6896 , G01N2333/4709 , G01N2800/2821
摘要： Amyloid binding compounds which are derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing Chrysamine G and derivatives thereof and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
摘要翻译： 描述了作为Chrysamine G的衍生物的淀粉样蛋白结合化合物，含有药物组合物的方法，以及使用这些化合物在体内鉴定阿尔茨海默氏病并诊断其它淀粉样变性特征的其他病理状态如唐氏综合征的方法。 还描述了含有Chrysamine G及其衍生物的药物组合物和使用这些组合物在淀粉样变性相关病症中预防细胞变性和淀粉样蛋白诱导的毒性的方法。 还描述了使用Chrysamine G衍生物在活组织检查或尸检组织中染色或检测淀粉样蛋白沉积物的方法。 还描述了使用Chrysamine G衍生物来量化活检和尸体组织匀浆中的淀粉样蛋白沉积物的方法。
-
5.发明授权Compounds, compositions and methods for medical imaging of Parkinson's disease 有权用于帕金森病医学成像的化合物，组合物和方法公开(公告)号：US08329142B2
公开(公告)日：2012-12-11
申请号：US12178281
申请日：2008-07-23
CPC分类号： A61K49/10 , A61K51/0406 , G01N33/6896 , G01N2800/2835
摘要： Compounds, compositions and methods for the detection and diagnosis of Parkinson's disease. Derivative lycerophosphocholine (GPC) compounds are used as a detection and diagnostic aid to measure progression of Parkinson's disease by detecting GPC binding to α-synuclein. Derivative CPG compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging (MRI) and/or positron emission tomography (PET) applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the detection, diagnosis and assessment of the progression of Parkinson's disease may be achieved.
摘要翻译： 用于检测和诊断帕金森病的化合物，组合物和方法。 衍生的裂解磷酸胆碱（GPC）化合物用作检测和诊断辅助，通过检测GPC与α-突触核蛋白的结合来测量帕金森病的进展。 提出了包括GPC的非放射性，顺磁性和放射性衍生物的衍生CPG化合物。 这些化合物具有与原始GPC分子相似的结合特性，并且可用于医学磁共振成像（MRI）和/或正电子发射断层摄影（PET）应用。 通过结合本发明的组合使用这些放射技术，可以实现帕金森病进展的检测，诊断和评估。
-
6.发明申请Method and System for Differential Diagnosis of Chronic Schizophrenia and Chronic Alcoholism 审中-公开慢性精神分裂症和慢性酒精中毒鉴别诊断方法与系统公开(公告)号：US20130211227A1
公开(公告)日：2013-08-15
申请号：US13584254
申请日：2012-08-13
CPC分类号： A61B5/0042 , A61B5/055 , A61B5/14546 , A61B5/4064 , A61B5/4076 , A61K31/22
摘要： Biomarker diagnosis of chronic schizophrenia in the presence of cognitive impairment is confirmed when Phosphocreatine (PCr) levels are increased, compared to normal levels, in both the left and right prefrontal cortices of the brain, with increased PCr specifically also in the left basal ganglia and also reduced NA/Crt in the left superior temporal region of the brain. Biomarker differential diagnosis is also taught for chronic alcoholism (with or without cognitive impairment) and for chronic schizophrenia even when cognitive impairment is absent.
摘要翻译： 当认知障碍存在时，慢性精神分裂症的生物标志物诊断被确认，当与左侧和右侧前额叶皮层相比，磷酸肌酸（PCr）水平与正常水平相比增加时，PCr特异性也在左侧基底神经节和 也降低了大脑左上颞区的NA / Crt。 慢性酒精中毒（有或没有认知障碍）和慢性精神分裂症也被认为是生物标志物鉴别诊断，即使不存在认知障碍。
-
7.发明授权Compounds, compositions and methods for medical imaging of neuropsychiatric disorders 有权用于神经精神障碍的医学成像的化合物，组合物和方法公开(公告)号：US07815894B2
公开(公告)日：2010-10-19
申请号：US10854894
申请日：2004-05-27
CPC分类号： G01N33/6896 , A61K49/10 , A61K51/0406 , G01N2800/2821
摘要： Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the β-turn of beta amyloid (Aβ) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
摘要翻译： 用于诊断阿尔茨海默病的化合物，组合物和方法。 合成的甘油磷酸胆碱（GPC）可用作诊断阿尔茨海默氏病进展的诊断辅助。 GPC是一种能够特异性结合β-淀粉样蛋白（A＆bgr））肽的膜磷脂代谢产物。 提出了包括GPC的非放射性，顺磁性和放射性衍生物的化合物。 这些化合物具有与原始GPC分子相似的结合特性，并且可用于医学磁共振成像和/或正电子发射断层摄影应用。 通过结合本发明的组合物使用这些放射技术，可以实现阿尔茨海默病进展的诊断和评估。
-
8.发明授权Compounds, compositions and methods for treating neuropsychiatric disorders 失效用于治疗神经精神障碍的化合物，组合物和方法公开(公告)号：US07407778B2
公开(公告)日：2008-08-05
申请号：US11198761
申请日：2005-08-05
IPC分类号： C12P21/04 , A61K35/78 , A61K31/225 , A01B79/00 , A01N37/30
CPC分类号： A61K36/28 , A23L33/175 , A23V2002/00 , A61K31/205 , A61K31/22 , A61K31/221 , A61K2300/00 , A23V2250/0612 , A23V2200/322
摘要： Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an aseptic environment to alter carbohydrate consumption and feedback repress gluconeogenesis. Large shifts in sunflower seed fatty acid, phospholipid and high-energy metabolism change the germination environment and these metabolic changes lead to an approximate 1000-fold increase in natural LCAR and ALCAR production by the seeds. The resulting LCAR and ALCAR products from the seeds are used for treating mental health disorders including Alzheimer's disease, geriatric depression, non-geriatric depression and schizophrenia.
摘要翻译： 乙酰 -
L - 肉碱（ALCAR）和L-卡汀（LCAR）是营养药物，具有治疗各种精神健康障碍的适应症。 提出了一种代谢组学指导的生物过程方法来增强发芽植物种子中的 A LCAR和LCAR形成。 通过生物反应器中的萌发来操作代谢通量以增加氧的可用性，并提供无菌环境来改变碳水化合物消耗和反馈抑制糖异生。 向日葵种子脂肪酸，磷脂和高能量代谢的大量变化会改变萌发环境，这些代谢变化导致种子自然LCAR和ALCAR产量增加近1000倍。 来自种子的所得LCAR和ALCAR产品用于治疗精神健康障碍，包括阿尔茨海默病，老年抑郁症，非老年抑郁症和精神分裂症。 -
9.发明授权Method and system for differential diagnosis of chronic schizophrenia and chronic alcoholism 有权慢性精神分裂症和慢性酒精中毒鉴别诊断方法与系统公开(公告)号：US08894973B2
公开(公告)日：2014-11-25
申请号：US13584254
申请日：2012-08-13
IPC分类号： A61B5/055 , A61K49/00 , A61K39/00 , A61K39/38 , A61K39/12 , A61K39/21 , A61K39/29 , A61B5/00 , A61B5/145 , A61K31/22
CPC分类号： A61B5/0042 , A61B5/055 , A61B5/14546 , A61B5/4064 , A61B5/4076 , A61K31/22
摘要： The invention is a method for the differential diagnosis of chronic schizophrenia or chronic alcoholism, by imaging the brain of a subject to detect any or all of the markers phosphocreatine (PCr), N-acetyl aspartate divided by the total creatine signal (NA/Crt), and synaptic phosphodiester (sPDE), and determining any increase or decrease in the presence of such markers compared to normal levels in specified anatomic areas of the brain. The output of such a method, resulting from such imaging, is presented to be viewed by a diagnostician in order to support the differential diagnosis based on the data output.
摘要翻译： 本发明是用于鉴别慢性精神分裂症或慢性酒精中毒的方法，通过对受试者的脑进行成像以检测任何或所有标记物磷酸肌酸（PCr），N-乙酰天冬氨酸除以总肌酸信号（NA / Crt ）和突触磷酸二酯（sPDE），并且与脑的指定解剖区域中的正常水平相比，确定这些标志物存在的任何增加或减少。 由这种成像产生的这种方法的输出被呈现给诊断者来观察，以便基于数据输出支持鉴别诊断。
-
10.发明申请COMPOUNDS, COMPOSITIONS AND METHODS FOR PRODUCING ANTIOXIDANTS FROM CARNITINE 有权化合物，组合物和方法从CARNITINE生产抗氧化剂公开(公告)号：US20090069423A1
公开(公告)日：2009-03-12
申请号：US12183609
申请日：2008-07-31
IPC分类号： A61K31/225 , C12P13/00 , A61P25/28
CPC分类号： A61K31/22 , A23L33/175 , A23P20/105 , A23V2002/00 , A61K31/225 , A61K36/28 , A23V2250/0612 , A23V2200/322 , A23V2200/02
摘要： Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are used as a natural nutritional source of powerful human antioxidants.
摘要翻译： 肉碱是具有治疗各种精神健康障碍的营养药物。 提出代谢组学指导的生物过程方法，用于在发芽植物种子中产生肉碱的长链脂肪酸酯，如多不饱和脂肪酸酯，包括二十碳五烯酰基-L-肉碱和/或二十二碳六烯基-L-肉毒碱。 来自植物种子的所得产品被用作强大的人类抗氧化剂的天然营养来源。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.032 秒)
